Express Pharma
Home  »  Market  »  Lupin gets USFDA approval for Sevelamer Carbonate Tablets

Lupin gets USFDA approval for Sevelamer Carbonate Tablets

They are indicated for the control of serum phosphorus in adults and children six years of age and older with chronic kidney disease on dialysis

0 172
Read Article

Lupin has received approval for its Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration (US FDA), to market a generic equivalent of Renvela Tablets, 800 mg, of Genzyme Corporation.

Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children six years of age and older with chronic kidney disease on dialysis.

Sevelamer Carbonate Tablets (RLD: Renvela) had estimated annual sales of $348 million in the US (IQVIA MAT September 2020).

Leave A Reply

Your email address will not be published.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Attend India's Largest Pharma Packaging & Labelling Conclave
Register Now
close-image